27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Eli Lilly And Co’s (NYSE:LLY) third-quarter results show the persisting impact of COVID-19 and pricing headwinds, according to BofA Securities.
The Eli Lilly Analyst: Geoff Meacham maintained a Buy rating on Eli Lilly with a $180 price target.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Eli Lilly Thesis: The downbeat third-quarter results could exert pressure on the company’s stock, Meacham said in the note.
Eli Lilly missed both top- and bottom-line estimates for the quarter.
In the third quarter, the company “saw an impact from pricing pressures (+5% sales growth, +9% volume growth) particularly with Trulicity and increased expenses (+9% y/y), which was driven by COVID-19 development expenses ($125M),” the analyst said.
Lilly's year-to-date growth “still remains strong / differentiated which is a key part of the story, with revenues growing +6% (driven primarily by volume growth),” he said.
Lilly maintained the 2020 guidance for revenue and non-GAAP earnings, “assuming a rebound in healthcare activity and modest pricing headwinds from patient affordability programs and changes in segment mix,” Meacham said.
LLY Price Action: Shares of Eli Lilly were down 6.14% at $133 at last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.